韩国青少年2型糖尿病缓解期的临床特点

IF 4.7 Q1 ENDOCRINOLOGY & METABOLISM
Sohyun Shin, Hwa Young Kim, Se Young Kim, Jaehyun Kim
{"title":"韩国青少年2型糖尿病缓解期的临床特点","authors":"Sohyun Shin, Hwa Young Kim, Se Young Kim, Jaehyun Kim","doi":"10.7570/jomes24042","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Improving β-cell function can lead to remission in some patients with type 2 diabetes mellitus (T2DM). However, research on pharmacotherapy-induced remission in youth-onset T2DM remains scarce. Our study aimed to identify the clinical characteristics of pediatric patients who experience remission.</p><p><strong>Methods: </strong>We retrospectively reviewed 88 pediatric patients with T2DM followed for at least 1 year at Seoul National University Bundang Hospital between 2013 and 2023. Remission was defined as a glycosylated hemoglobin (HbA1c) level less than 6.5% for at least 3 months after ceasing glucose-lowering pharmacotherapy.</p><p><strong>Results: </strong>Among 88 patients (60 males, 68.2%) diagnosed at an average age of 14.4±2.1 years, 19 patients (21.6%) achieved remission after a median duration of 1.4 years. The remission group had a larger proportion of males (89.5% vs. 62.3%, <i>P</i>=0.024) and a lower urinary microalbumin-to-creatinine ratio (ACR) at diagnosis (<i>P</i>=0.011). They also showed lower HbA1c levels at 1 year and more significant changes in HbA1c and body mass index (all <i>P</i><0.05). Higher urinary ACR levels correlated with a longer duration to achieve remission (hazard ratio, 0.928; <i>P</i>=0.013). In three of the 19 remission patients (15.8%), recurrence occurred after a median of 1.5 years.</p><p><strong>Conclusion: </strong>Among Korean youth with T2DM, 21.6% achieved remission after a median duration of 1.4 years. Those who experienced remission were predominantly male, had lower ACR at diagnosis, and had significant weight loss within the first year. Further investigation into the factors influencing remission and long-term outcomes is essential.</p>","PeriodicalId":45386,"journal":{"name":"Journal of Obesity & Metabolic Syndrome","volume":" ","pages":""},"PeriodicalIF":4.7000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical Characteristics of Korean Youth-Onset Type 2 Diabetes Mellitus Patients in Remission.\",\"authors\":\"Sohyun Shin, Hwa Young Kim, Se Young Kim, Jaehyun Kim\",\"doi\":\"10.7570/jomes24042\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Improving β-cell function can lead to remission in some patients with type 2 diabetes mellitus (T2DM). However, research on pharmacotherapy-induced remission in youth-onset T2DM remains scarce. Our study aimed to identify the clinical characteristics of pediatric patients who experience remission.</p><p><strong>Methods: </strong>We retrospectively reviewed 88 pediatric patients with T2DM followed for at least 1 year at Seoul National University Bundang Hospital between 2013 and 2023. Remission was defined as a glycosylated hemoglobin (HbA1c) level less than 6.5% for at least 3 months after ceasing glucose-lowering pharmacotherapy.</p><p><strong>Results: </strong>Among 88 patients (60 males, 68.2%) diagnosed at an average age of 14.4±2.1 years, 19 patients (21.6%) achieved remission after a median duration of 1.4 years. The remission group had a larger proportion of males (89.5% vs. 62.3%, <i>P</i>=0.024) and a lower urinary microalbumin-to-creatinine ratio (ACR) at diagnosis (<i>P</i>=0.011). They also showed lower HbA1c levels at 1 year and more significant changes in HbA1c and body mass index (all <i>P</i><0.05). Higher urinary ACR levels correlated with a longer duration to achieve remission (hazard ratio, 0.928; <i>P</i>=0.013). In three of the 19 remission patients (15.8%), recurrence occurred after a median of 1.5 years.</p><p><strong>Conclusion: </strong>Among Korean youth with T2DM, 21.6% achieved remission after a median duration of 1.4 years. Those who experienced remission were predominantly male, had lower ACR at diagnosis, and had significant weight loss within the first year. Further investigation into the factors influencing remission and long-term outcomes is essential.</p>\",\"PeriodicalId\":45386,\"journal\":{\"name\":\"Journal of Obesity & Metabolic Syndrome\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-04-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Obesity & Metabolic Syndrome\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.7570/jomes24042\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Obesity & Metabolic Syndrome","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7570/jomes24042","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

背景:改善β细胞功能可导致部分2型糖尿病(T2DM)患者病情缓解。然而,关于青年发病T2DM药物治疗诱导缓解的研究仍然很少。我们的研究旨在确定经历缓解的儿科患者的临床特征。方法:我们回顾性分析了2013年至2023年在首尔国立大学盆唐医院随访至少1年的88例2型糖尿病儿童患者。缓解被定义为糖化血红蛋白(HbA1c)水平在停止降糖药物治疗后至少3个月低于6.5%。结果:88例患者(60例男性,68.2%)平均诊断年龄为14.4±2.1岁,19例患者(21.6%)在中位持续时间为1.4年后获得缓解。缓解组男性比例较大(89.5% vs. 62.3%, P=0.024),诊断时尿微量白蛋白与肌酐比值(ACR)较低(P=0.011)。他们在1年后的HbA1c水平也较低,HbA1c和体重指数的变化更显著(所有PP=0.013)。19例缓解患者中有3例(15.8%)在中位1.5年后复发。结论:在韩国青年T2DM患者中,21.6%的患者在中位持续时间1.4年后获得缓解。那些经历缓解的主要是男性,在诊断时有较低的ACR,并且在第一年有明显的体重减轻。进一步调查影响缓解和长期预后的因素是必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Clinical Characteristics of Korean Youth-Onset Type 2 Diabetes Mellitus Patients in Remission.

Background: Improving β-cell function can lead to remission in some patients with type 2 diabetes mellitus (T2DM). However, research on pharmacotherapy-induced remission in youth-onset T2DM remains scarce. Our study aimed to identify the clinical characteristics of pediatric patients who experience remission.

Methods: We retrospectively reviewed 88 pediatric patients with T2DM followed for at least 1 year at Seoul National University Bundang Hospital between 2013 and 2023. Remission was defined as a glycosylated hemoglobin (HbA1c) level less than 6.5% for at least 3 months after ceasing glucose-lowering pharmacotherapy.

Results: Among 88 patients (60 males, 68.2%) diagnosed at an average age of 14.4±2.1 years, 19 patients (21.6%) achieved remission after a median duration of 1.4 years. The remission group had a larger proportion of males (89.5% vs. 62.3%, P=0.024) and a lower urinary microalbumin-to-creatinine ratio (ACR) at diagnosis (P=0.011). They also showed lower HbA1c levels at 1 year and more significant changes in HbA1c and body mass index (all P<0.05). Higher urinary ACR levels correlated with a longer duration to achieve remission (hazard ratio, 0.928; P=0.013). In three of the 19 remission patients (15.8%), recurrence occurred after a median of 1.5 years.

Conclusion: Among Korean youth with T2DM, 21.6% achieved remission after a median duration of 1.4 years. Those who experienced remission were predominantly male, had lower ACR at diagnosis, and had significant weight loss within the first year. Further investigation into the factors influencing remission and long-term outcomes is essential.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Obesity & Metabolic Syndrome
Journal of Obesity & Metabolic Syndrome ENDOCRINOLOGY & METABOLISM-
CiteScore
8.30
自引率
9.60%
发文量
39
审稿时长
19 weeks
期刊介绍: The journal was launched in 1992 and diverse studies on obesity have been published under the title of Journal of Korean Society for the Study of Obesity until 2004. Since 2017, volume 26, the title is now the Journal of Obesity & Metabolic Syndrome (pISSN 2508-6235, eISSN 2508-7576). The journal is published quarterly on March 30th, June 30th, September 30th and December 30th. The official title of the journal is now "Journal of Obesity & Metabolic Syndrome" and the abbreviated title is "J Obes Metab Syndr". Index words from medical subject headings (MeSH) list of Index Medicus are included in each article to facilitate article search. Some or all of the articles of this journal are included in the index of PubMed, PubMed Central, Scopus, Embase, DOAJ, Ebsco, KCI, KoreaMed, KoMCI, Science Central, Crossref Metadata Search, Google Scholar, and Emerging Sources Citation Index (ESCI).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信